Company profile: Cyclenium Pharma
1.1 - Company Overview
Company description
- Provider of next-generation macrocyclic drug discovery technology (CMRT) and the QUEST library of small-molecule macrocycles to identify novel therapeutics for difficult disease targets. Offers collaborative drug discovery, out-licensing of advanced leads (e.g., anti-flaviviral agents, opioid receptor agonists), and in-licensing opportunities in oncology and anti-infectives.
Products and services
- Collaborative Drug Discovery: Integrated partnerships granting access to CMRT Technology and the QUEST Library for drug discovery and optimization against difficult targets in oncology and infectious diseases
- CMRT Technology: Proprietary macrocyclic small‑molecule drug discovery system that targets difficult disease targets to identify novel therapeutics addressing areas of unsatisfied medical need in oncology and infectious diseases
- QUEST Library: Curated collection of macrocyclic compounds offering broad spatial coverage and topological diversity to support drug discovery for challenging disease targets
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cyclenium Pharma
Antares Pharma
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products and drug-delivery technologies leveraging proprietary platforms, including ENHANZE® for subcutaneous delivery that can reduce hours-long IV infusions to minutes-long injections; subcutaneous and intramuscular auto-injectors; HYLENEX® recombinant to facilitate dispersion and absorption of injected drugs; XYOSTED® CIII testosterone enanthate injection; and a partner auto-injector pipeline used in five approved therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antares Pharma company profile →
Roquefort Therapeutics
HQ: United Kingdom
Website
- Description: Provider of pre-clinical anti-cancer therapeutics, including Midkine-targeting antibodies; antisense oligonucleotides to reduce Midkine in cancer cells; gene-editing RNA and mRNA therapies for solid tumors; STAT-6 siRNA therapeutics; and MK cell therapy with direct and NK cell-mediated action, advancing candidates toward clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Roquefort Therapeutics company profile →
Lewis and Clark Pharmaceuticals
HQ: United States
Website
- Description: Provider of early-stage pharmaceutical development targeting treatments for arthritis, diabetes, glaucoma, and atherosclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lewis and Clark Pharmaceuticals company profile →
Cellerix
HQ: Spain
Website
- Description: Provider of adult stem cell-based medicines and therapies for gastroenterology, dermatology, and immune-based diseases, including Cx401 for the treatment of complex perianal fistulas.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellerix company profile →
PD-Rx Pharmaceuticals
HQ: United States
Website
- Description: Provider of quality products and personal customer service to the healthcare industry.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PD-Rx Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cyclenium Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cyclenium Pharma
2.2 - Growth funds investing in similar companies to Cyclenium Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cyclenium Pharma
4.2 - Public trading comparable groups for Cyclenium Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →